Zymeworks

Zymeworks ZYME Stock

$26.04   0.773997%
Add to favorites
Market Cap
$1.83B
LOW - HIGH [24H]
$24.88 - $26.24
VOLUME [24H]
$1.02M
P/E Ratio
49.13
Earnings per share
$0.53
ISIN
US98985Y1082
Price   Prediction

Zymeworks Price Chart

Sorry, that's all we've gotfor now...

Zymeworks (ZYME) stock price today is 26.04 USD on Tech Market Large (+0.77% on the day). Updated .

Zymeworks ZYME Financial and Trading Overview

Zymeworks stock price 26.04 USD
Previous Close 26.45 USD
Open 26.45 USD
Bid 18.72 USD x 200
Ask 33.03 USD x 200
Day's Range 25.53 - 26.52 USD
52 Week Range 21.52 - 31.97 USD
Volume 569.92K USD
Avg. Volume 1.08M USD
Market Cap 1.81B USD
Beta (5Y Monthly) 1.304
PE Ratio (TTM) 48.75472
EPS (TTM) 0.53 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 43.29 USD

ZYME Valuation Measures

Enterprise Value 1.74B USD
Trailing P/E 48.75472
Forward P/E 87.10015
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 6.8127894
Price/Book (mrq) 7.1223817
Enterprise Value/Revenue 6.529
Enterprise Value/EBITDA 26.657

Trading Information

Zymeworks Stock Price History

Beta (5Y Monthly) 1.304
52-Week Change 14.33%
S&P500 52-Week Change 10.51%
52 Week High 31.97 USD
52 Week Low 21.52 USD
50-Day Moving Average 27.22 USD
200-Day Moving Average 25.56 USD

ZYME Share Statistics

Avg. Volume (3 month) 1.08M USD
Avg. Daily Volume (10-Days) 1.07M USD
Shares Outstanding 68.7M
Float 63.9M
Short Ratio 4.35
% Held by Insiders 1.34%
% Held by Institutions 105.58%
Shares Short 5.91M
Short % of Float 12.88%
Short % of Shares Outstanding 8.22%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 16.28%
Operating Margin (ttm) 22.58%
Gross Margin 51.68%
EBITDA Margin 24.49%

Management Effectiveness

Return on Assets (ttm) 4.77%
Return on Equity (ttm) 14.97%

Income Statement

Revenue (ttm) 265.97M USD
Revenue Per Share (ttm) 3.61 USD
Quarterly Revenue Growth (yoy) 828.70%
Gross Profit (ttm) 137.46M USD
EBITDA 65.14M USD
Net Income Avi to Common (ttm) 43.31M USD
Diluted EPS (ttm) 0.53
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 100.46M USD
Total Cash Per Share (mrq) 1.46 USD
Total Debt (mrq) 53.13M USD
Total Debt/Equity (mrq) 20.57 USD
Current Ratio (mrq) 3.297
Book Value Per Share (mrq) 3.628

Cash Flow Statement

Operating Cash Flow (ttm) -111964000 USD
Levered Free Cash Flow (ttm) -195686752 USD

Profile of Zymeworks

Country United States
State DE
City Middletown
Address 108 Patriot Drive
ZIP 19709
Phone 302 274 8744
Website https://www.zymeworks.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 279

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Q&A For Zymeworks Stock

What is a current ZYME stock price?

Zymeworks ZYME stock price today per share is 26.04 USD.

How to purchase Zymeworks stock?

You can buy ZYME shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Zymeworks?

The stock symbol or ticker of Zymeworks is ZYME.

Which industry does the Zymeworks company belong to?

The Zymeworks industry is Biotechnology.

How many shares does Zymeworks have in circulation?

The max supply of Zymeworks shares is 70.12M.

What is Zymeworks Price to Earnings Ratio (PE Ratio)?

Zymeworks PE Ratio is 49.13208000 now.

What was Zymeworks earnings per share over the trailing 12 months (TTM)?

Zymeworks EPS is 0.53 USD over the trailing 12 months.

Which sector does the Zymeworks company belong to?

The Zymeworks sector is Healthcare.

Zymeworks ZYME included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.16B USD — 24225.3 USD — 24538.78 USD — — 7.16B USD —
us US Tech Global Select Market Com NQGS US 12034.87 USD —
+0.42
— — 11933.12 USD — 12087.81 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
us NYSE Composite Index NYA US 23559.61 USD —
-1.06
— — 23530.84 USD — 23742.73 USD — — — —
$2.17T
Total marketcap
$71.27B
Total volume
BTC 58.00%   •   ETH 9.96%
Dominance
Select currency